Altimmune to Present at Two Upcoming Virtual Investor Conferences

GAITHERSBURG, Md., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

• H.C. Wainwright Hepatitis B Virus (HBV) Virtual ConferenceTuesday, October 20, 2020 – 1:30 pm EDT

• B. Riley Securities – Liver Disease SymposiumThursday, October 29, 2020

The H.C. Wainwright HBV presentation will be webcast and can be accessed by visiting the investor relations section of the company's website at www.altimmune.com under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:

Stacey Jurchison	Ashley R. Robinson
Altimmune, Investor Relations	LifeSci Advisors, LLC
Phone: 410-474-8200	617-430-7577
[email protected]	[email protected]

Source: Altimmune, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Northeast Ohio Medical University (NEOMED) Mobilizes Global Health Resources for Nepal Disaster Response and Recovery
• Global pharmacy leaders identify priorities for integrating pharmacists into primary health care
• Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera